Skip to content
Cefamandole nafate
Mandol (cefamandole nafate) is a small molecule pharmaceutical. Cefamandole nafate was first approved as Mandol on 1982-01-01. It is used to treat bacterial pneumonia, bacterial skin diseases, escherichia coli infections, haemophilus infections, and infectious bone diseases amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefamandole nafate
Tradename
Company
Number
Date
Products
MANDOLEli LillyN-050504 DISCN1982-01-01
4 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192—
infectious bone diseases—D001850—
klebsiella infectionsEFO_1001353D007710—
proteus infectionsEFO_1001130D011512—
soft tissue infections—D018461—
staphylococcal infections—D013203A49.01
streptococcal infectionsEFO_1001476D013290—
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DC: Second-generation cephalosporins
— J01DC03: Cefamandole
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EndocarditisD004696EFO_0000465I33———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFAMANDOLE NAFATE
INNcefamandole
Description
Cefamandole is a cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups. It has a role as an antibacterial drug. It is a cephalosporin and a semisynthetic derivative. It is a conjugate acid of a cefamandole(1-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cn1nnnc1SCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1.[Na+]
Identifiers
PDB—
CAS-ID34444-01-4
RxCUI2178
ChEMBL IDCHEMBL1618
ChEBI ID3481
PubChem CID456255
DrugBankDB01326
UNII ID5CKP8C2LLI (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,613 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,324 adverse events reported
View more details